Esophageal Cancer – Pipeline Review, H1 2013

Published: June 2013
No. of Pages: 136
   

Summary

Global Markets Direct’s, ''Esophageal Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Cancer. Esophageal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Esophageal Cancer.
  • A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Esophageal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Esophageal Cancer – Pipeline Review, H1 2013

Table Of Contents

Table Of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Esophageal Cancer 11
Esophageal Cancer Therapeutics under Development by Companies 13
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Esophageal Cancer Therapeutics – Products under Development by Companies 21
Esophageal Cancer Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Esophageal Cancer Therapeutics Development 24
Bristol-Myers Squibb Company 24
Shionogi & Co., Ltd. 25
Tekmira Pharmaceuticals Corp. 26
Bavarian Nordic A/S 27
Gilead Sciences, Inc. 28
Novartis AG 29
Cell Therapeutics, Inc. 30
Takara Bio Inc. 31
Synta Pharmaceuticals Corp. 32
Transgene Biotek Ltd 33
Proteo, Inc. 34
Supratek Pharma Inc. 35
GANYMED Pharmaceuticals AG 36
Advantagene, Inc. 37
Merrimack Pharmaceuticals, Inc. 38
Omeros Corporation 39
BioStar Pharmaceuticals, Inc. 40
Kringle Pharma, Inc. 41
ImmunoFrontier, Inc. 42
RECEPTA Biopharma S.A. 43
Esophageal Cancer – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
brivanib alaninate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
paclitaxel poliglumex - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BMS-833923 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
panobinostat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ganetespib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
doxorubicin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Elafin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NK-4 Protein - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MM-111 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
IMAB-362 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
celecoxib + [cisplatin] + [irinotecan hydrochloride] + Radiation Therapy - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
bevacizumab + [docetaxel] + [oxaliplatin] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
nimotuzumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
nimotuzumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
IMF-001 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
nedaplatin + [docetaxel] - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Peptide Vaccine + [cisplatin] + [fluorouracil ] + [Montanide ISA-51] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Peptide Cancer Vaccine + [basiliximab] - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TCR Gene Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TKM-PLK1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] + [leucovorin calcium] - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
NEO-201 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Autologous Tumor Cell Vaccine + [celecoxib] + [Iscomatrix] - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GPR39 Antagonist - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
TBL-0805E - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Drug For Esophageal Cancer - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Xiao''aiping - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
First Generation Attenuated Strain Of Reovirus - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Esophageal Cancer Therapeutics – Drug Profile Updates 103
Esophageal Cancer Therapeutics – Discontinued Products 122
Esophageal Cancer Therapeutics - Dormant Products 123
Esophageal Cancer – Product Development Milestones 126
Featured News & Press Releases 126
May 15, 2013: Synta Pharma Announces Presentations On Ganetespib Clinical Trials At 2013 ASCO Annual Meeting 126
Oct 25, 2012: Novelos Announces Enrollment Of First Patient In Solid Tumor Imaging Trial With I-124-CLR1404 At University Of Wisconsin Carbone Cancer Center 127
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Results Of MM-111 At European Society for Medical Oncology 2012 127
Oct 01, 2012: MethylGene Presents Clinical Data On MGCD265 At European Society For Medical Oncology 2012 Congress 129
Jun 08, 2012: Cancer Research UK Launches Trial Of Experimental Drug Combination For Advanced Stomach And Oesophageal Cancer 130
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute 131
Feb 23, 2011: Proteo''s Elafin Shortens Intensive Care After Surgery For Esophagus Cancer 132
Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO In American Journal Of Clinical Oncology 132
Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of Side Effects In Patients With Advanced Esophageal Cancer 133
Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin In The Treatment Of Oesophagus Carcinoma 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 136

List Of Tables

Number of Products Under Development for Esophageal Cancer, H1 2013 11
Products under Development for Esophageal Cancer – Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2013 23
Bristol-Myers Squibb Company, H1 2013 24
Tekmira Pharmaceuticals Corp., H1 2013 26
Bavarian Nordic A/S, H1 2013 27
Gilead Sciences, Inc., H1 2013 28
Novartis AG, H1 2013 29
Cell Therapeutics, Inc., H1 2013 30
Takara Bio Inc., H1 2013 31
Synta Pharmaceuticals Corp., H1 2013 32
Transgene Biotek Ltd, H1 2013 33
Proteo, Inc., H1 2013 34
Supratek Pharma Inc., H1 2013 35
GANYMED Pharmaceuticals AG, H1 2013 36
Advantagene, Inc., H1 2013 37
Merrimack Pharmaceuticals, Inc., H1 2013 38
Omeros Corporation, H1 2013 39
BioStar Pharmaceuticals, Inc., H1 2013 40
Kringle Pharma, Inc., H1 2013 41
ImmunoFrontier, Inc., H1 2013 42
RECEPTA Biopharma S.A., H1 2013 43
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Stage and Molecule Type, H1 2013 49
Esophageal Cancer Therapeutics – Drug Profile Updates 103
Esophageal Cancer Therapeutics – Discontinued Products 122
Esophageal Cancer Therapeutics – Dormant Products 123
Esophageal Cancer Therapeutics – Dormant Products (Contd..1) 124
Esophageal Cancer Therapeutics – Dormant Products (Contd..2) 125

List Of Figures

Number of Products under Development for Esophageal Cancer, H1 2013 11
Products under Development for Esophageal Cancer – Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Route of Administration, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Molecule Type, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 49

Published By: Global Markets Direct
Product Code: Global Markets Direct6256


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100